A benefit-risk review of systemic haemostatic agents - Part 2: In excessive or heavy menstrual bleeding

Drug Safety

Volumn 31, Issue 4, 2008, Pages 275-282

  Fraser, Ian S ^a   Porte, Robert J ^b   Kouides, Peter A ^c   Lukes, Andrea S ^d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c Mary M Gooley Hemophilia Center   (United States)

^d Carolina Women's Research and Wellness Center   (United States)

Author keywords

Antihaemorrhagics, adverse reactions; Antihaemorrhagics, therapeutic use; Benefit risk assessment; Danazol, adverse reactions; Danazol, therapeutic use; Desmopressin, adverse reactions; Desmopressin, therapeutic use; Etamsylate, therapeutic use

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; DANAZOL; DESMOPRESSIN; DESOGESTREL PLUS ETHINYLESTRADIOL; DICLOFENAC; DYDROGESTERONE; ESTROGEN; ETAMSYLATE; ETHINYLESTRADIOL PLUS GESTODENE; FLURBIPROFEN; GESTAGEN; GONADORELIN AGONIST; GOSERELIN; HEMOSTATIC AGENT; IBUPROFEN; INDOMETACIN; LEVONORGESTREL; MECLOFENAMIC ACID; MEDROXYPROGESTERONE ACETATE; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PLASMIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNINDEXED DRUG;

ABDOMINAL PAIN; ACNE; ALOPECIA; AMENORRHEA; ARTERY THROMBOSIS; BLEEDING DISORDER; BLOATING; BLOOD DISEASE; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; BRONCHOSPASM; DIGESTIVE SYSTEM ULCER; DIZZINESS; FATIGUE; FEMALE FERTILITY; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HEADACHE; HEMOLYTIC ANEMIA; HIRSUTISM; HOT FLUSH; HUMAN; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPONATREMIA; LEG PAIN; LIBIDO DISORDER; LIPOPROTEIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR SURGERY; MENSTRUATION; MENSTRUATION DISORDER; MOOD CHANGE; MUSCLE CRAMP; NAUSEA; NIGHT SWEAT; OBSTRUCTIVE JAUNDICE; OILY SKIN; PELVIS PAIN SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RASH; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN MANIFESTATION; SPOTTING; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; VAGINAL DRYNESS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; VIRILIZATION; VOICE CHANGE; VOMITING; VON WILLEBRAND DISEASE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONTRACEPTIVES, ORAL, COMBINED; DANAZOL; DEAMINO ARGININE VASOPRESSIN; FEMALE; GONADOTROPIN-RELEASING HORMONE; HEMOSTATICS; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MENORRHAGIA; PROGESTINS; RISK ASSESSMENT; TRANEXAMIC ACID;

EID: 41149098045     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831040-00001     Document Type: Review

References (70)

1. Fraser IS, Porte RJ, Kouides PA, et al. A benefit-risk review of systemic haemostatic agents. Part 1: in major surgery. Drug Saf 2008; 31 (3): 217-30
2. Osei J, Critchley H. Menorrhagia, mechanisms and targeted therapies. Current Opin Obstet Gynecol 2005; 17 (4): 411-8
3. Protheroe J. Modern management of menorrhagia. J Fam Plann Reprod Health Care 2004; 30 (2): 118-22
4. Kadir RA, Lukes AS, Kouides PA, et al. Management of excessive menstrual bleeding in women with hemostatic disorders. Fertil Steril 2005; 84 (5): 1352-9
5. Demers C, Derzko C, David M, et al. Gynaecological and obstetric management of women with inherited bleeding disorders. Int J Gynaecol Obstet 2006 Oct; 95 (1): 75-87
6. FFPRHC guidance (April 2004): the levonorgestrel-releasing intrauterine system (LNG-IUS) in contraception and reproductive health. J Fam Plann Reprod Health Care 2004; 30 (2): 99-109
7. National Institute for Health and Clinical Excellence. Heavy menstrual bleeding: NICE clinical guidance 44 [online]. Available from URL: http://www.nice.org [Accessed 2007 Jan 15]
8. Oehler MK, Rees MCP. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82 (5): 405-22
9. Leissinger C, Becton D, Cornell Jr C, et al. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A. Haemophilia 2001 May; 7 (3): 258-66
10. Kujovich JL. Von Willebrand's disease and menorrhagia: prevalence, diagnosis, and management. Am J Hematol 2005; 79 (3): 220-8
11. ClinicalTrials.gov. Treatment and management of women with bleeding disorders [online]. Available from URL: http://clinicaltrials.gov [Accessed 2005 may 18]
12. World Health Organization. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995; 346: 1575-82.
13. Dockeray CJ, Sheppard BL, Daly L, et al. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987; 24 (4): 309-18
14. Edlund M, Blomback M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin. Blood Coagul Fibrinolysis 2003; 14: 593-8
15. Hahn L, Cederblad G, Rybo G, et al. Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss. Br J Obstet Gynaecol 1976 Dec; 83 (12): 974-80
16. Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding. Clinical update on safety. Therapeutic Advances 1991; (4): 1-8
17. Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003; 63 (13): 1417-33
18. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (4): CD000249
19. Gleeson NC, Buggy F, Sheppard BL, et al. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994 Mar; 73 (3): 274-7
20. Preston JT, Cameron IT, Adams EJ, et al. Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995 May; 102 (5): 401-6
21. Ylikorkala O, Viinikka L. Comparison between antifibrinolytic and antiprostaglandin treatment in the reduction of increased menstrual blood loss in women with intrauterine contraceptive devices. Br J Obstet Gynaecol 1983 Jan; 90 (1): 78-83
22. Kriplani A, Kulshrestha V, Agarwal N, et al. Role of tranexamic acid in management of dysfunctional uterine bleeding in comparison with medroxyprogesterone acetate. J Obstet Gynaecol 2006 Oct; 26 (7): 673-8
23. Bonnar J, Sheppard BL. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid. BMJ 1996 Sep 7; 313 (7057): 579-82
24. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products (CPMP) opinion following an article 10 referral: Cyklo-f [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/ referral/090200en.pdf [2000 Jul 27]
25. Mohri H. High dose of tranexamic acid for treatment of severe menorrhagia in patients with von Willebrand disease. J Thromb Thrombolysis 2002 Dec; 14 (3): 255-7
26. Berntorp E, Follrud C, Lethagen S. No increased risk of venous thrombosis in women taking tranexamic acid [letter]. Thromb Haemost 2001 Aug; 86 (2): 714-5
27. Medicines and Healthcare products Regulatory Agency (MHRA). Consultation letter ARM 39: Cyclo-F 500mg tablets [online]. Available from URL: http://www.mhra.gov.uk [Accessed 2008 Feb 1]
28. Kadir RA, Lee CA, Sabin CA, et al. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study. Haemophilia 2002 Nov; 8 (6): 787-93
29. Edlund M, Blomback M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time. Blood Coagul Fibrinolysis 2002 Apr; 13 (3): 225-31
30. Roy SN, Bhattacharya S. Benefits and risks of pharmacological agents used for the treatment of menorrhagia. Drug Saf 2004; 27 (2): 75-90
31. Lopez Bernal A, Buckley S, Rees CM, et al. Meclofenamate inhibits prostaglandin E binding and adenylyl cyclase activation in human myometrium. J Endocrinol 1991 Jun; 129 (3): 439-45
32. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (2): CD000400
33. Rees MC, Canete-Soler R, Lopez Bernal A, et al. Effect of fenamates on prostaglandin E receptor binding. Lancet 1988 Sep 3; 2 (8610): 541-2
34. Vargyas JM, Campeau JD, Mishell Jr DR. Treatment of menorrhagia with meclofenamate sodium. Am J Obstet Gynecol 1987 Oct; 157 (4 Pt 1): 944-50
35. Chamberlain G, Freeman R, Price F, et al. A comparative study of ethamsylate and mefenamic acid in dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991 Jul; 98 (7): 707-11
36. Laupacis A, Fergusson D. Drugs to minimize perioperative blood loss in cardiac surgery: meta-analyses using perioperative blood transfusion as the outcome. Anesth Analg 1997; 85 (6): 1258-67
37. Coulter A, Kelland J, Peto V, et al. Treating menorrhagia in primary care: an overview of drug trials and a survey of prescribing practice. Int J Technol Assess Health Care 1995 Summer; 11 (3): 456-71
38. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2006; (2): CD003855
39. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000; (2): CD001016
40. Middeldorp S. Oral contraceptives and the risk of venous thromboembolism. Gend Med 2005; 2 Suppl. A: S3-9
41. Tanis BC, Rosendaal FR. Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Sem Vasc Med 2003; 3 (1): 69-83
42. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007 May; 75 (5): 344-54
43. European Active Surveillance study on prescribing practice. The European Active Surveillance study on oral contraceptives (EURAS-OC) [online]. Available from URL: http://www.euras-drugsurveillance.info/index.html [Accessed 2007 May 1]
44. Conard J, Plu-Bureau G, Bahi N, et al. Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception 2004 Dec; 70 (6): 437-41
45. American College of Obstetricians and Gynaecologists. Management of anovulatory bleeding. Washington, DC: American College of Obstetricians and Gynaecologists (ACOG), 2000. ACOG practice bulletin no.14 [online]. Available from URL: http://www.guideline.gov [Accessed 2000 Mar 9]
46. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS): a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006 Mar 1; 125 (1): 9-28
47. Lethaby AE, Cooke I, Rees M. Progesterone or progestogen releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005; (4): CD002126
48. Reid PC, Mukri F. Trends in number of hysterectomies performed in England for menorrhagia: examination of health episode statistics, 1989 to 2002-3. BMJ 2005 Apr 23; 330 (7497): 938-9
49. Mansour D. Overview of contraception methods: a provider's perspective. In: Glasier A, Wellings K, Critchley H, editors. Contraception and contraceptive use. London: RCOG Press, 2005: 44-77
50. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 2007 Jun; 75 (6 Suppl.): S161-6
51. Kingman CE, Kadir RA, Lee CA, et al. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 2004 Dec; 111 (12): 1425-8
52. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998 Jun; 105 (6): 592-8
53. Reid PC, Virtanen-Kari S. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts. BJOG 2005 Aug; 112 (8): 1121-5
54. Health Canada. Levonorgestrel-releasing intrauterine sytem and uterine perforation. Canadian Adverse Reaction Newsletter 2006; 16 (1): 2
55. Nilsson L, Rybo G. Treatment of menorrhagia. Am J Obstet Gynecol 1971 Jul 1; 110 (5): 713-20
56. Fraser IS, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol 1991 Feb; 31 (1): 66-70
57. ClinicalTrials.gov. A multicenter, double-blind, randomized, parallel-group, placebo-controlled, 7 cycle duration of oral SH T00658ID tablets for the treatment of dysfunctional uterine bleeding. NCT 00293059 [online]. Available from URL: http://clinical trials.gov [Accessed 2006 Feb 15]
58. ClinicalTrials.gov. A multicenter, double-blind, randomized, parallel-group, placebo-controlled, 7 cycle duration of oral SH T00658ID tablets for the treatment of dysfunctional uterine bleeding. NCT 00307801 [online]. Available from URL: http://clinicaltrials.gov [Accessed 2006 Mar 27]
59. Belicova M, Lukac B, Dvorsky J, et al. Thromboembolic disease and present oral contraception. Clin Appl Thromb Hem 2003; 9 (1): 45-51
60. Quehenberger P, Loner U, Kapiotis S, et al. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives. Thromb Haemost 1996 Nov; 76 (5): 729-34
61. Kemmeren JM, Algra A, Grobbee DE. Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ 2001 Jul 21; 323 (7305): 131-4
62. Gomes MP, Deitcher SR. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review. Arch Intern Med 2004 Oct 11; 164 (18): 1965-76
63. Farmer RD, Lawrenson RA, Todd JC, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000 Jun; 49 (6): 580-90
64. Alvarado RG, Liu JY, Zwolak RM. Danazol and limb-threatening arterial thrombosis: two case reports. J Vasc Surg 2001 Dec; 34 (6): 1123-6
65. Corno M, Vallar G, Scarlato G, et al. Danazol and internal carotid artery thrombosis. Eur Neurol 1989; 29 (4): 235-7
66. Satake R, Arakawa S, Hashimoto M, et al. Successful direct thrombolysis in a patient with extensive dural sinus thrombosis induced by danazol [in Japanese]. J Clin Neurol 1997; 37 (4): 309-13
67. Garay RP, Chiavaroli C, Hannaert P. Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent. Am J Ther 2006 May-2006 30; 13 (3): 236-47
68. DeVore GR, Owens O, Kase N. Use of intravenous premarin in the treatment of dysfunctional uterine bleeding: a double-blind randomized control study. Obstet Gynecol 1982 Mar; 59 (3): 285-91
69. Porte RJ, Leebeek FWG. Pharmacological strategies to decrease transfusion requirements in patients undergoing surgery. Drugs 2002; 62 (15): 2193-211
70. Warren MP. A comparative review of the risks and benefits of hormone replacement therapy regimens. Am J Obstet Gynecol 2004; 190 (4): 1141-67